Epiodyne
San Francisco, US · Founded 2016 · Delaware corporation · 4 known investors
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.
BiotechHealthtechMedical Devices
Founders & leadership
Epiodyne was founded in 2016 by Brian Shoichet.
BS
Brian ShoichetFounder
DC
Douglas Crawford, Ph.D.CEO
DG
Don Gehlert, Ph.D.Head of Biology
Board
DC
Investors · 4
Reported raises · per SEC filings
Form D private placements$14.3M disclosed across 3 rounds · 2016–2018
▶$8MraisedApr 2019 · 13 investors · BiotechnologyRule 506(b)
▶$8MraisedApr 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alex TkachenkoExecutive Officer, Director
- Brook ByersDirector
- Douglas CrawfordDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5.8MraisedNov 2017 · 3 investors · BiotechnologyRule 506(b)
▶$5.8MraisedNov 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brook ByersDirector
- Douglas CrawfordDirector
- Alex TkachenkoExecutive Officer, Director
- Offering amount
- $10.1M
- Amount sold
- $5.8M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$500KraisedJun 2016 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas CrawfordExecutive Officer, Director
- Brian ShoichetDirector
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Epiodyne do?
- Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.
- Who founded Epiodyne?
- Epiodyne was founded by Brian Shoichet in 2016.
- Who are Epiodyne's investors?
- Epiodyne's investors include Menlo Ventures, Mission Bay Capital, Mission Biocapital, Kleiner Perkins.
- How much funding has Epiodyne raised?
- Epiodyne has disclosed $14.3M raised across 3 rounds.
- Where is Epiodyne headquartered?
- Epiodyne is headquartered in San Francisco, US.